Literature DB >> 19804425

Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years.

Chung Cheng Wang1, Michael B Chancellor, Jyh Ming Lin, Jui Hsiang Hsieh, Hong Jeng Yu.   

Abstract

OBJECTIVE: To investigate the association of type 2 diabetes mellitus (T2DM) and metabolic syndrome with lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) in Taiwanese men aged <45 years. PATIENTS, SUBJECTS AND METHODS: Voiding and erectile function in 226 men with T2DM, at one diabetes clinic, and 183 healthy men with normal fasting blood glucose levels, were compared. Participants were evaluated using the International Prostate Symptom Score (IPSS), the five-item version of the International Index of Erectile Function questionnaire (IIEF-5), and measurements of flow rate and postvoid residual urine volume. The association of metabolic syndrome with LUTS and ED was also evaluated.
RESULTS: The mean (sd, range) age of the patients was 38.9 (6.1, 20-45) years and the mean duration of diabetes was 2.8 (3.1, 0.5-20) years. Compared with controls, men with T2DM had a significantly mean (sd) higher IPSS, of 6.1 (5.8) vs 4.1 (4.6) (P < 0.001), an increased of odds ratio (95% confidence interval) of having moderate to severe LUTS of 1.78 (1.12-2.84) (P = 0.01), greater voiding volume of 376 (177) vs 326 (102) mL (P = 0.04), a worse IIEF-5 score of 17.3 (6.4) vs 20.0 (3.8) (P < 0.001), an increased of odds ratio of having moderate to severe ED of 3.5 (2.1-5.8) (P < 0.001) but a similar maximum flow rate and postvoid residual. The IIEF-5 score was negatively correlated with the IPSS (P < 0.0001, coefficient = -0.23, 0.35-0.11) and glycosylated haemoglobin (P = 0.02, coefficient = -0.14, 0.26-0.01). In all, 156 (69%) patients met the criteria for metabolic syndrome. The mean age, duration of diabetes, glycosylated haemoglobin, IPSS, voided volume, maximum urinary flow rate and IIEF-5 score were similar between patients with and without metabolic syndrome.
CONCLUSIONS: Men with T2DM and aged <45 years had more LUTS but a similar bladder emptying function than the controls. ED was highly prevalent and was associated with the severity of LUTS. Metabolic syndrome did not aggravate the severity of LUTS, emptying function or ED in the early stage of DM.
© 2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2009        PMID: 19804425     DOI: 10.1111/j.1464-410X.2009.08913.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series.

Authors:  Nino Cristiano Chilelli; Giuseppe Bax; Giulio Bonaldo; Eugenio Ragazzi; Massimo Iafrate; Filiberto Zattoni; Federico Bellavere; Annunziata Lapolla
Journal:  Endocrine       Date:  2017-04-18       Impact factor: 3.633

2.  GreenLight laser photoselective vaporization of the prostate for treatment of benign prostate hyperplasia/lower urinary tract symptoms in patients with different post-void residual urine.

Authors:  Fei Luo; Hong-Hong Sun; Yan-Hui Su; Zhi-Hua Zhang; Ya-Shen Wang; Zhen Zhao; Jian Li
Journal:  Lasers Med Sci       Date:  2017-03-14       Impact factor: 3.161

3.  Association of urinary nerve growth factor levels with erectile function in young men with type 2 diabetes mellitus.

Authors:  C-C Wang; C-H Liao; H-T Liu; J-M Lin; H-C Kuo
Journal:  Int J Impot Res       Date:  2017-02-09       Impact factor: 2.896

4.  The Relationship Between Diabetes, Diabetes Severity, Diabetes Biomarkers, and the Presence of Lower Urinary Tract Symptoms: Findings From the National Health and Nutrition Examination Survey.

Authors:  Christopher A Tam; Brian T Helfand; Bradley A Erickson
Journal:  Urology       Date:  2017-04-06       Impact factor: 2.649

Review 5.  Hyperglycemia and insulin resistance and the risk of BPH/LUTS: an update of recent literature.

Authors:  Benjamin N Breyer; Aruna V Sarma
Journal:  Curr Urol Rep       Date:  2014-12       Impact factor: 3.092

6.  Is metabolic syndrome truly a risk factor for male lower urinary tract symptoms or just an epiphenomenon?

Authors:  Marina Zamuner; Walker Wendell Laranja; João Carlos Cardoso Alonso; Fabiano A Simões; Ronald F Rejowski; Leonardo O Reis
Journal:  Adv Urol       Date:  2014-01-23

7.  Lower urinary tract symptoms and erectile dysfunction in men with type 2 diabetes mellitus.

Authors:  Hyo Jeong Song; Eun Joo Lee; Nancy Bergstrom; Duck-Hee Kang; Dae Ho Lee; Gwangpyo Koh; Jung-Sik Huh; Sung Dae Kim; Seong Cheol Hong; Seong Sil Moon; Jiyoung Kang
Journal:  Int Neurourol J       Date:  2013-12-31       Impact factor: 2.835

8.  Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.

Authors:  Chung-Cheng Wang; Cheng-Ling Lee; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2016-03-18       Impact factor: 4.546

Review 9.  Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome.

Authors:  Abdulmaged M Traish; Vanessa Johansen
Journal:  World J Mens Health       Date:  2018-07-03       Impact factor: 5.400

Review 10.  The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A.

Authors:  Chung-Cheng Wang; Yung-Hong Jiang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2020-03-16       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.